Esperite (ESP.AS) Stock Price

Esperite Price

Euronext·CLOSED
0
​
Market closed

Over the last 13 years Esperite grew revenue by 7.6% annually, reaching 16.55 M EUR. Earnings per share have grown at 0.4% per year over the last 6 years. For Esperite, the net margin of -76.9% is down versus -11.8% a few years ago. The dividend has grown at 15.5% per year over the past 2 years.

Esperite stock price

Access this data via the Eulerpool API

Esperite business model & stock analysis

Esperite NV is a company based in the Netherlands that specializes in the development, production, and marketing of stem cell and cell therapies. It focuses on creating groundbreaking therapies for the treatment of serious diseases and aims to market them worldwide. Its business model includes three main segments: Life Science, Consumer Healthcare, and Branding. The Life Science segment focuses on developing stem cell and cell therapies for the treatment of diseases such as autism, cancer, and degenerative disorders. The Consumer Healthcare segment offers products related to pregnancy and fertility assistance. The Branding segment involves the development and marketing of high-quality cosmetic products. Esperite's flagship product is CryoSave, a solution for the long-term preservation of stem cells from umbilical cord blood.

Frequently asked questions about Esperite

The business model of Esperite NV focuses on offering innovative solutions in the field of biotechnology, particularly in the area of stem cells. Esperite NV, a company based in the Netherlands, is dedicated to the development and commercialization of advanced therapies for regenerative medicine, cellular therapy, and personalized medicine. This includes the collection, processing, storage, and distribution of stem cells from multiple sources, such as umbilical cord blood and tissue. By leveraging their expertise and partnerships, Esperite NV aims to provide valuable medical services and products that contribute to improving patient outcomes and healthcare advancements.

Esperite NV is primarily active in the healthcare industry.

Esperite NV faces competition from several companies in the market. Some of its main competitors include Cryo-Save Group, StemCare, and FamilyCord. These companies also operate in the field of stem cell banking and offer similar services. However, Esperite NV distinguishes itself through its innovative technology and extensive global presence. It strives to maintain a competitive edge by continuously advancing its product offerings and expanding its customer base.

Esperite NV is a company with a rich history and background. Established in 2000, Esperite NV, formerly known as Cryo-Save Group NV, is a leading biotech company specializing in the collection, processing, and storage of stem cells obtained from umbilical cord blood and tissue. The company has an extensive global presence, operating multiple cryopreservation and processing laboratories across Europe and South Africa. Through its subsidiary, Cryo-Save, Esperite NV has successfully stored over 325,000 samples, providing families with a valuable resource for future medical treatments. With a strong commitment to research and innovation, Esperite NV continues to contribute significantly to the advancement of regenerative medicine and stem cell-based therapies.

Esperite NV, a renowned company in the stock market, has achieved several significant milestones. Over the years, Esperite NV has successfully expanded its global presence, establishing a strong foothold in the field of cell therapy and biobanking. With strategic partnerships and collaborations with industry leaders, Esperite NV has propelled innovation and advancements in stem cell research. Additionally, the company has consistently delivered breakthrough technologies, contributing to the development of groundbreaking medical solutions. Esperite NV's commitment to excellence and dedication to its stakeholders have led to consistent growth and enhanced shareholder value, making it a leading player in the stock market.

Esperite NV, a renowned company in the stock market, primarily operates in various countries and regions. It has a significant presence in the European market, with a focus on countries such as the Netherlands, Spain, Belgium, and the United Kingdom. Additionally, Esperite NV extends its reach to key regions including the Middle East and North Africa. With its diversified portfolio and strategic partnerships, Esperite NV has established a strong foothold in these regions, allowing it to cater to a wide range of investors and stakeholders.

Esperite NV represents values of innovation, scientific excellence, and commitment to improving healthcare solutions. With a strong corporate philosophy centered around pioneering stem cell technologies, Esperite NV is dedicated to unlocking the therapeutic potential of stem cells for regenerative medicine. By leveraging its extensive expertise in cryopreservation and biomedical services, the company aims to empower patients and healthcare professionals with state-of-the-art tools for personalized medicine. Esperite NV's commitment to quality, safety, and ethical practices resonates throughout its operations, ensuring the utmost integrity in delivering advanced healthcare solutions.

The Esperite share (ESP.AS) is listed on 3 stock exchanges, including: London (0OMG.L), Amsterdam (ESP.AS).

Esperite NV is a Dutch company specializing in life sciences. It operates a diversified business model consisting of various divisions to achieve its goals in research and development and the provision of services to the medical industry. The company's primary division is the biological cell banking unit, operating under the brand name CryoSave. CryoSave collects stem cells from umbilical cord blood and tissue, dental pulp, milk teeth, adipose tissue, and other tissues with high healing potential. These stem cells are used in the treatment of diseases such as diabetes, cancer, neurological disorders, and other serious conditions. The company also operates the Progenity AB division, a biotech company specializing in the development and production of solutions for cell transfection and culture. Progenity AB also provides services for in vitro research, such as cell line development, cell culture provision, and management. Esperite NV also operates the DNA amplification division, operating under the brand name LifeCode. LifeCode is a leading provider of DNA amplification solutions for the forensic, medical, and scientific community. LifeCode's solutions include reagents and instruments for polymerase chain reaction (PCR) and other amplification and sequencing technologies. Additionally, the company is also involved in the field of animal health, particularly in cattle breeding. Esperite NV's animal health division operates under the name Cryo-Save Agro, providing leading services in cattle semen and genetic advisory services to breeders. In addition to its businesses in biological research and development, Esperite NV is also involved in clinical trials. The company provides services for the planning of clinical trials, development of protocols, and data management for studies. Esperite NV also operates a charity organization, the Cord for Life Foundation, which functions as a nonprofit organization collecting funds for charitable purposes to support stem cell research and development and promote public awareness of the benefits of stem cell therapies. In summary, Esperite NV operates a diverse business model focusing on the research and development of biological solutions and services. With its divisions in biological cell banking, cell transfection and culture, DNA amplification, animal health, and clinical trials, the company offers a wide range of products and services to its customers, contributing to the advancement of science in the field of regenerative medicine and driving progress in the medical industry.

The revenue cannot currently be calculated for Esperite.

The profit cannot currently be calculated for Esperite.

The P/E ratio cannot be calculated for Esperite at the moment.

The P/S cannot be calculated for Esperite currently.

The Eulerpool Quality Score for Esperite is 1/10.

The ISIN of Esperite is NL0009272137. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of Esperite is ESP.AS. The ticker symbol is used to trade Esperite shares on the stock exchange.

Fair ValueTerminal
148.30 EUR
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Biotechnology
Number of shares
Employees
Revenue per Employee
80,746.34 EUR
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Website esperite.com
Country
Netherlands
Currency
EUR
Initial public offering
Oct 1, 2009
ISIN
NL0009272137
Cusip
N3070G108
Sedol
B4TBMF0
Market capitalization
52-Week Range
PEG
—
P/E ratio
P/Ee
—
P/S
P/Se
—
EV/EBIT
—
P/B Ratio
0.34
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-169.18 %
Last updated Oct 14, 2026, 10:13 AM

Esperite Ticker

AMSTERDAM · ESP.ASEURONEXT · ESP.ASLONDON · 0OMG.L

Esperite FIGI

CRYVF:UV · BBG000VHK193CRYOUSD:XS · BBG0015GYKX8CRYOEUR:XS · BBG002K0N514CRYOEUR:EU · BBG0058LZZF1ESP:FP · BBG006RZ8HH5ESPA:B3 · BBG006TPG4H5ESPA:L3 · BBG006TPNBC6ESPA:PO · BBG008GZM9T2ESPA:L1 · BBG00Y90YC29

All fundamentals and in-depth analysis of Esperite

Our stock analysis for Esperite stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Esperite. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.